Joint + Gluco Control VSL and Ads Analysis: What the Sales Pitch Really Says

What Is Joint + Gluco Control?

Joint + Gluco Control is a dietary supplement sold direct-to-consumer, positioned as a complete joint-repair "protocol" rather than a simple daily capsule. The VSL presents it as the culmination of a $1 billion, three-year cross-disciplinary research program, though no institutional name is ever attached to that program. The product's physical format is a kit-style offering mailed to the buyer; the VSL references a "three-week protocol" and a one-time payment of $23 with free shipping, suggesting a single-package purchase rather than a subscription model.

In terms of market positioning, Joint + Gluco Control sits at the intersection of two fast-growing supplement subcategories: joint health (a global market the Grand View Research firm estimated at over $12 billion in 2023) and "ancient mineral" wellness products, a category that has expanded considerably on the back of consumer interest in trace minerals, sea salts, and pre-industrial nutritional sources. The product's stated differentiator is not that it contains glucosamine or chondroitin, the standard actives in most pharmacy joint supplements, but that it delivers magnesium, potassium, boron, and 84 additional trace elements via pink Himalayan salt, which the VSL claims functions as a superior mineral delivery vehicle.

The target user, as defined by the VSL's testimonials and language, is an American between 55 and 80 years old who has been living with chronic joint pain long enough to have tried conventional treatments and found them inadequate. This is a buyer who has already cycled through ibuprofen, prescription NSAIDs, cortisone injections, and possibly physical therapy, someone for whom the medical system has become a source of frustration rather than relief, and who is therefore receptive to a message that frames that frustration as the result of deliberate suppression rather than the genuine complexity of degenerative joint disease.

The Problem It Targets

Chronic joint pain is not a niche problem dressed up to seem larger than it is. According to the Centers for Disease Control and Prevention (CDC), approximately 58.5 million American adults have been diagnosed with some form of arthritis, and the number is projected to reach 78 million by 2040 as the population ages. Osteoarthritis alone, the degenerative joint disease the VSL most directly addresses, affects roughly 32.5 million Americans, making it one of the most prevalent chronic conditions in the country. The economic burden, including healthcare costs and lost productivity, exceeds $300 billion annually, according to the Arthritis Foundation. These are not numbers the VSL invents; the scale of the problem is real, and the VSL is smart enough to know that a genuinely massive, underserved market requires no exaggeration to seem urgent.

What the VSL does invent is the explanation for why the problem persists. The script builds its case around a concept it calls "mineral starvation", the assertion that joints fail not because of mechanical wear, inflammatory autoimmune responses, or genetic predisposition, but because the body lacks specific trace minerals required to produce synovial fluid and regenerate cartilage. This framing is rhetorically effective because it takes a real and partially true observation (modern processed diets are indeed lower in many trace minerals than pre-industrial diets, and mineral deficiencies can affect musculoskeletal health) and extends it far beyond what the research supports. The National Institutes of Health (NIH) has published research showing that magnesium deficiency is associated with higher inflammatory markers and that boron may play a role in bone metabolism, but there is no peer-reviewed evidence that supplementing with pink Himalayan salt reverses established osteoarthritis or restores measurably degraded cartilage in humans.

The VSL's framing of the problem is designed to do one specific thing: shift the target buyer from a patient identity ("I have a disease that requires medical management") to a victim identity ("I have been denied a simple mineral solution by a system that profits from my suffering"). This is not an accidental reframing. It is a deliberate narrative move, what direct-response copywriters call the false enemy frame, that transforms the product's competitors (doctors, pharmaceuticals, the healthcare system) into antagonists and positions the seller as the only honest party in the room. Once a buyer accepts that framing, their critical filters for evaluating the product's actual claims are significantly lowered.

The problem framing also relies heavily on a specific statistical claim: that "84% of joint pain sufferers develop irreversible complications within five to seven years" without intervention. This number appears twice in the script and is never sourced. No equivalent figure appears in the CDC's arthritis surveillance data, the American College of Rheumatology's clinical guidelines, or any major epidemiological study this analysis could locate. Its function in the script is not informational, it is loss aversion engineering, a tactic drawn directly from Kahneman and Tversky's Prospect Theory, designed to make inaction feel like an active choice toward catastrophic harm.

How Joint + Gluco Control Works

The mechanism the VSL proposes rests on three linked claims, each of which requires separate evaluation. The first claim is that synovial fluid, the lubricating liquid inside joint capsules, degrades primarily because the body lacks the mineral precursors to produce it. The second is that chondrocytes, the cells responsible for maintaining cartilage, can be "reactivated" from a dormant state by supplying those minerals, particularly magnesium, potassium, and boron. The third is that this reactivation happens measurably within 17 hours of consumption. Each step in this chain contains a kernel of established biology that is then extended into territory the science does not currently support.

The role of chondrocytes in cartilage maintenance is well-established. Research published in Osteoarthritis and Cartilage and reviewed by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) confirms that chondrocyte dysfunction is central to osteoarthritis progression, and that stimulating anabolic chondrocyte activity is a legitimate therapeutic target. Hyaluronic acid, which the VSL references as the "basis of joint lubrication", is a real and important component of synovial fluid, and its synthesis does depend on metabolic processes that require micronutrient cofactors. So the biological vocabulary in the script is not fabricated; it is selectively assembled. The problem is the leap from "these minerals are involved in joint-related metabolic pathways" to "consuming them in a pink salt supplement restores cartilage in 17 hours."

The 17-hour timeline is the claim that strains credibility most severely. Cartilage is avascular, it has no direct blood supply and receives nutrients only through the slow diffusion of synovial fluid. This makes it one of the slowest-healing tissues in the human body. Sports medicine literature consistently describes cartilage repair processes in weeks to months, not hours, even when therapeutic interventions like platelet-rich plasma injections or pharmaceutical-grade hyaluronic acid are used. The claim that a mineral supplement delivered orally could produce "noticeable relief" within 17 hours is not impossible if interpreted narrowly, some ingredients like magnesium have genuine anti-inflammatory effects that can reduce pain perception in that timeframe, but the VSL presents this timeline as evidence of structural cartilage restoration, which is a different and unsupported assertion entirely.

The cytokine-reduction mechanism mentioned later in the script ("this method lowers the bad signals called cytokines that cause swelling and joint damage") is the most scientifically plausible element of the proposed mechanism. Magnesium supplementation has been shown in multiple human trials to reduce circulating levels of C-reactive protein and interleukin-6, two key inflammatory cytokines implicated in joint pain. If Joint + Gluco Control delivers a meaningful dose of bioavailable magnesium, it could produce genuine anti-inflammatory effects, which would be a real benefit, even if the mechanism is far more modest than the VSL claims.

Curious how other VSLs in this niche structure their pitch? Keep reading, the section below breaks down the psychology behind every claim made above.

Key Ingredients and Components

The VSL identifies a relatively small set of active ingredients by name, framing them as a "unique mineral complex" rather than a proprietary blend of standard supplement actives. The formulation appears simple, intentionally so, because simplicity is itself a persuasive signal in a market saturated with complex multi-ingredient joint stacks.

Below is an ingredient-level evaluation based on publicly available research:

• Pink Himalayan Salt, A mineral-rich rock salt mined primarily in the Khewra Salt Mine in Pakistan. It does contain trace amounts of minerals beyond sodium chloride, including iron (which gives it its characteristic color), magnesium, potassium, and calcium. The claim that it contains "84 trace elements" has been cited by multiple salt marketers but is not independently verified by peer-reviewed compositional analysis. The mineral concentrations in pink Himalayan salt are real but typically present in quantities far below therapeutic doses, a fact the VSL does not address.

• Magnesium, The most scientifically supported ingredient in the implied formulation. Magnesium deficiency is prevalent in Western populations (NIH estimates suggest nearly 50% of Americans consume less than the recommended daily amount), and supplementation has been shown in multiple randomized controlled trials to reduce inflammatory markers and improve pain perception. A 2020 review in Nutrients (Rosique-Esteban et al.) found significant associations between magnesium intake and lower systemic inflammation. The benefit is real; the question is dose and bioavailability, neither of which the VSL specifies.

• Potassium, An essential electrolyte involved in muscle function and fluid balance. Some research suggests potassium plays a role in maintaining alkaline pH, which may reduce uric acid crystallization relevant to gout. Its direct role in cartilage regeneration or synovial fluid production is not well-supported in the peer-reviewed literature.

• Boron, The most interesting ingredient cited, and the one with the most direct joint-health research. Studies reviewed by the NIH's Office of Dietary Supplements suggest boron influences the metabolism of calcium, magnesium, and vitamin D, all factors in bone and cartilage health. A small clinical study published in Environmental Health Perspectives (Nielsen, 1990) found that boron supplementation reduced arthritic symptoms in a subset of patients. The evidence is preliminary and the study is dated, but it is not fabricated.

• Hyaluronic Acid precursors (implied), The VSL references "high aluronic acid" (a phonetic approximation of hyaluronic acid) as the target output of its mechanism, not as a direct ingredient. Injectable hyaluronic acid for knee osteoarthritis has an established clinical evidence base, reviewed by Cochrane Collaboration meta-analyses, though the effect sizes are modest. Whether oral precursors can meaningfully increase synovial hyaluronic acid concentrations remains debated in the literature.

Hooks and Ad Angles

The VSL's opening move is among the most aggressive in the health supplement space: it impersonates a network news broadcast, positions a globally recognized technology billionaire as its protagonist, and delivers what functions as a pattern interrupt of exceptional force, a disruption of the viewer's ad-recognition system before that system has a chance to engage. The opening line, "this morning the world was shocked by sensational news," is calibrated to a cognitive register that signals genuine news, not advertising. By the time the viewer recognizes they are watching a sales letter, the emotional and narrative investment required to continue watching has already been made.

In terms of market sophistication theory, a framework Eugene Schwartz developed in Breakthrough Advertising (1966) to describe how buyers evolve through stages of skepticism, this VSL is operating at Stage 4 or Stage 5. The target buyer has already seen every direct claim ("reduces joint pain!"), every mechanism claim ("rebuilds cartilage!"), and every social proof arrangement. They have been burned before. The only message that can reach them is one that (a) explains why everything they've tried has failed through no fault of their own, and (b) comes packaged in a credibility wrapper so novel that it temporarily suspends their skepticism. Impersonating Lester Holt and Elon Musk is a brute-force solution to a Stage 5 market: when no claim is believable on its own, borrow the credibility of names so famous they feel pre-verified.

The secondary hooks within the VSL serve a stacking function, each reinforcing the emotional state the opening hook created:

• "Our team found a leaked copy of the video and you're about to see it now", deploys forbidden-knowledge framing to intensify curiosity
• "Pain pays and healthy joints don't", a punchy epigram that crystallizes the conspiracy narrative
• "84% of joint pain sufferers develop irreversible complications within five to seven years", statistical shock designed to convert passive viewers into urgent buyers
• "They banned his social accounts right after he shared it", censorship framing that makes the product feel dangerous to powerful interests
• "Why did they keep this from us for so long?", rhetorical open loop that primes the buyer to experience the product's reveal as a moment of liberation

For media buyers testing variations on Meta or YouTube, the following headline angles are derivable from the VSL's strongest structural moves:

• "The $23 mineral kit that canceled 3 surgeries last month, doctors are furious"
• "Pink Himalayan salt and your joint pain: what nobody in orthopedics will tell you"
• "She was scheduled for knee replacement at 68. Then she found this."
• "Why 30,500 people skipped their pain prescription after using this mineral protocol"
• "The 17-hour joint fix that Big Pharma spent $1 billion trying to suppress"

Psychological Triggers and Persuasion Tactics

The persuasive architecture of this VSL is not a random accumulation of sales techniques. It is a sequenced system in which each layer of persuasion is built on top of the previous one, creating what behavioral economists call a commitment escalation path. The viewer who accepts the news broadcast framing as legitimate has already committed to a belief state that makes the subsequent celebrity endorsement more plausible; the viewer who accepts the celebrity endorsement is primed to accept the clinical trial figures; the viewer who accepts those figures is primed to accept the urgency and scarcity frame at the close. Each acceptance makes the next one cognitively easier, a structure that Robert Cialdini documented as the consistency principle in Influence (1984) and that online marketers have refined into a near-science.

The VSL is also notable for the way it handles anticipated objections by pre-empting them through the fake interviewer. The Lester Holt character voices the viewer's most likely resistance points ("I get the skepticism," "will people really be able to stop taking ibuprofen?") and then allows the Elon Musk character to dissolve them. This is a structural device from long-form advertorial writing, the fictional Q&A, that transforms what would be an unsupported assertion into what reads as an expert's candid admission under journalistic questioning. The viewer is not being sold to; they are "overhearing" a difficult conversation between a journalist and a reluctant truth-teller.

Specific tactical deployments worth examining:

• False authority (Cialdini's Authority principle): The impersonation of Elon Musk and Lester Holt is the VSL's central persuasion engine. It borrows two forms of authority simultaneously, scientific-inventor credibility (Musk) and journalistic verification credibility (Holt), neither of which the product has earned or been granted.
• Conspiracy framing and false enemy (Godin's Tribes): Big Pharma, regulators, and the medical establishment are constructed as a unified villain, placing the buyer in an in-group of people who have "seen through the system." Once inside that identity frame, rejecting the product feels like rejoining the villain's side.
• Loss aversion via disease statistics (Kahneman & Tversky's Prospect Theory): The repeated claim that inaction leads to irreversible complications within five to seven years reframes the purchase decision as risk management, not consumption.
• Price anchoring (Thaler's mental accounting): The sequential price reduction from $5,000 to $1,600 to $23 is executed in three distinct steps, each with a rationale (pharmacy markup, partner subsidies), creating the psychological sensation of an extraordinary deal rather than a product at its natural price point.
• Artificial scarcity (Cialdini's Scarcity principle): The claim of 1,100 remaining units and a 36-month restock delay is designed to override deliberation. A buyer who is still thinking critically when the video ends is a buyer who will not convert.
• Social proof stacking: Five testimonials, each thanking Elon Musk by name, serve the dual purpose of validating the product and reinforcing the celebrity association, every expression of gratitude is also an endorsement of the celebrity frame.
• Epiphany bridge narrative (Russell Brunson's framework): The Musk character narrates the moment of discovery, analyzing Mars rover data, noticing an earthly mineral, constructing the "what if" question, in a way that invites the viewer to experience the same intellectual revelation, converting the sales pitch into a shared discovery moment.

Want to see how these tactics compare across 50+ VSLs in the health and wellness space? That's exactly what Intel Services is built to show you.

Scientific and Authority Signals

The authority architecture of this VSL is sophisticated in its construction and almost entirely fabricated in its substance. The two named figures, Elon Musk and Lester Holt, are real people whose names carry extraordinary weight, but neither has any documented connection to a joint pain supplement, a mineral research program, or any "civilian access" government rollout. Elon Musk has no publicly known involvement in nutritional supplement development, and Lester Holt has made no such broadcast. The use of their identities constitutes impersonation, which violates Federal Trade Commission (FTC) guidelines on testimonials and endorsements (16 CFR Part 255) as well as the policies of every major digital advertising platform. It is not a gray area.

Beyond the celebrity framing, the VSL deploys a set of numerical authority signals that are carefully constructed to feel precise without being verifiable. The figures, "2,100 simulations," "$1 billion in research," "30,500 people tested," "100% success rate", follow a well-documented pattern in direct-response health advertising: specificity is used as a proxy for credibility. A claim that "over 30,000 people were tested" feels like an approximation; "30,500 people spanning every age" feels like it was pulled from a data report. The specificity is rhetorical, not scientific, no clinical trial of that scale, with that outcome uniformity, on a mineral-salt supplement has been published in any peer-reviewed journal accessible through PubMed or the Cochrane Library.

The references to government collaboration, a "civilian access program," and SpaceX/ISS involvement serve the same borrowed-authority function without even attaching a real institution's name. These are what can accurately be called ambiguous authority signals, references vague enough to avoid direct falsification but specific enough to imply institutional backing. The government, unnamed officials, and the ISS are all real and prestigious; their association with this product is invented.

What genuine scientific grounding exists in the VSL comes from the basic biology it accurately describes: chondrocytes do regenerate cartilage, synovial fluid does require metabolic precursors, magnesium does have anti-inflammatory properties, and boron has shown preliminary joint-health benefits in small studies. The NIH's Office of Dietary Supplements maintains evidence summaries on magnesium and boron that are publicly accessible and support modest, qualified claims. The distance between those modest qualified claims and the VSL's absolute promises, full recovery in three weeks, 100% success rate, elimination of all need for medical care, is the gap where the marketing operates and where the science does not follow.

The Offer, Pricing, and Risk Reversal

The offer construction in this VSL is a textbook example of extreme price anchoring deployed in sequence. The script begins by establishing a $5,000 price point attributed to the pharmacy channel ("If this went through pharmacies, they'd price it at $5,000 or more"), a figure presented as a systemic reality of pharmaceutical distribution rather than a rhetorical device. It then introduces the "original protocol cost" of $1,600, which functions as the seller's own anchor before the discount. The final price of $23 is positioned not as the product's actual market value but as an act of humanitarian mission, a framing that simultaneously justifies the improbably low price and discourages the buyer from questioning it. Whether the $5,000 or $1,600 figures bear any relationship to actual cost structures is never examined in the script, because the goal is not transparency but emotional contrast.

The guarantee is presented in deliberately personal terms: "I personally guarantee real lasting joint relief or your money back." This is a common guarantee structure in direct-response supplement marketing, and its risk-shifting function is real insofar as it places the formal refund obligation on the seller. However, the guarantee's value is complicated by the celebrity impersonation frame, if "Elon Musk" is guaranteeing the product, the actual legal entity responsible for refunds is obscured. A buyer who receives a product that does not perform as promised and attempts to invoke this guarantee will be dealing with an unknown company, not the person named in the guarantee.

The urgency and scarcity frame, 1,100 units remaining, sold out within an hour, 36-month restock delay, is standard direct-response pressure architecture. Whether the inventory figures are real is unknowable from the VSL alone, but the pattern is consistent with artificial scarcity as documented in FTC enforcement actions against supplement marketers. The 36-month restock claim is particularly notable because it dramatically extends the perceived consequence of inaction well beyond the typical "limited time offer" framing.

Who This Is For (and Who It Isn't)

The buyer this VSL is most precisely engineered to reach is a specific and real person: an American in their 60s or 70s who has been managing chronic joint pain for years, who has tried multiple pharmaceutical options with diminishing returns, who has significant distrust of institutional medicine born from lived experience, and who carries enough financial stress that $23 feels both affordable and proportionate to a problem this size. For this person, the VSL's conspiracy framing is not paranoid fantasy, it resonates with genuine experiences of feeling dismissed by doctors, over-medicated, and trapped in a system that treats symptoms rather than causes. The emotional intelligence embedded in the script is real, even when the science is not.

If you are researching this supplement from that position, years of pain, exhausted by conventional options, the honest assessment is this: the product almost certainly contains some real ingredients (magnesium, in particular) that have genuine anti-inflammatory effects and could produce perceptible pain reduction in some users. The 17-hour relief claim may not be as baseless as it first appears, if interpreted as anti-inflammatory effect rather than cartilage restoration. But the gap between what the ingredients can plausibly deliver and what the VSL promises is enormous, and the fabricated celebrity framing is a significant red flag about the seller's willingness to operate honestly.

The readers who should pass on this product without extended consideration are those who require reliable clinical evidence before making health decisions, those who are in active medical treatment for joint conditions and should not substitute supplements for prescribed care, and those who recognize that any seller willing to impersonate Elon Musk and Lester Holt to sell a $23 product has demonstrated, through that choice, a tolerance for deception that should inform every other claim they make.

Researching supplement marketing before you buy is exactly the kind of due diligence Intel Services exists to support. Keep reading for the FAQ and final analysis.

Frequently Asked Questions

Q: Is Joint + Gluco Control a scam?
A: The VSL employs fabricated celebrity endorsements (Elon Musk and Lester Holt are impersonated without their consent), invented clinical trial data, and artificial scarcity claims, all of which are deceptive marketing practices. Whether the underlying product delivers any benefit depends on its actual formulation, which the VSL does not fully disclose. The marketing architecture, however, contains multiple elements that regulators and consumer protection bodies classify as fraudulent.

Q: Did Elon Musk really invent a joint pain supplement?
A: No. There is no credible public record of Elon Musk developing, endorsing, or investing in any joint pain supplement or mineral health protocol. His name and likeness are used in this VSL without documented authorization, which is a form of celebrity impersonation that the FTC actively pursues in the supplement industry.

Q: Does pink Himalayan salt really help with joint pain?
A: Pink Himalayan salt does contain trace minerals including magnesium, potassium, and boron, all of which have some evidence base in musculoskeletal health research. However, the mineral concentrations in salt are generally far below therapeutic doses, and no clinical trial has demonstrated that pink Himalayan salt supplements restore cartilage or reverse osteoarthritis.

Q: Are there any side effects from Joint + Gluco Control?
A: The VSL claims "no side effects, no dependency", a claim that is difficult to evaluate without knowing the exact formulation and doses. Mineral supplements are generally well-tolerated, but excessive magnesium can cause gastrointestinal distress, and high sodium intake from salt-based products may be contraindicated for people with hypertension or kidney disease. Anyone with existing health conditions should consult a physician before adding mineral supplements.

Q: Is the 17-hour joint relief claim supported by science?
A: Not as stated. The claim implies structural cartilage restoration in 17 hours, which contradicts established understanding of cartilage biology, an avascular tissue that heals over weeks to months, not hours. Anti-inflammatory effects from magnesium could reduce pain perception within that timeframe, but that is a different and much more modest claim than the VSL makes.

Q: How fast does Joint + Gluco Control actually work?
A: The VSL claims noticeable relief within 17 hours and full joint recovery within three weeks. These timelines are not supported by peer-reviewed research on mineral supplementation for osteoarthritis. Individual responses to anti-inflammatory supplements vary significantly, and expecting surgical-candidate-level improvement within a week based on a $23 supplement protocol is not a realistic expectation grounded in clinical evidence.

Q: Does Joint + Gluco Control really work, or is it just hype?
A: The honest answer is that some ingredients with genuine anti-inflammatory properties may produce real, if modest, pain relief in some users. The product is likely not entirely inert. But the VSL's promises, 100% success rate across 30,500 people, full joint recovery, elimination of all need for medical care, are not supported by any independent evidence and represent a level of efficacy no mineral supplement has ever demonstrated in peer-reviewed research.

Q: Where can I buy Joint + Gluco Control and how much does it cost?
A: The VSL prices the product at $23 with free shipping, sold direct-to-consumer through a website linked below the video. Buyers should be aware that the company behind the product is not identified in the VSL, that the money-back guarantee is issued by a fabricated celebrity persona, and that the "scarcity" framing (1,100 units remaining) is a common artificial pressure tactic in this category.

Final Take

What this VSL reveals, more than anything about Joint + Gluco Control specifically, is the current state of direct-response health supplement marketing at its most aggressive boundary. The fabricated news broadcast format, the celebrity impersonation, the invented clinical trial data, none of these are new techniques. What is notable is how precisely they have been engineered for the specific cognitive profile of an older American in chronic pain who has lost faith in institutional medicine. The script does not misunderstand its audience; it understands them exceptionally well and exploits that understanding with considerable skill. The result is a piece of marketing that is simultaneously impressive as a persuasive artifact and genuinely concerning as a public health communication.

The strongest element of the VSL's underlying product concept is the one it underplays: the genuine evidence base for magnesium and boron in anti-inflammatory and musculoskeletal health applications. A supplement built around clinically meaningful doses of these minerals, marketed honestly, would have real selling points. The decision to abandon honest marketing in favor of Elon Musk impersonation and 17-hour cartilage claims suggests either that the actual formulation cannot support honest efficacy claims at therapeutic doses, or that the seller has calculated that the fabricated framing converts at a rate that justifies the regulatory risk. Neither possibility reflects well on the product.

For consumers, the analytical takeaway is not that mineral supplementation for joint health is worthless, the literature does not support that conclusion. The takeaway is that a seller willing to impersonate two of the most recognized figures in American public life to sell a $23 supplement has made a clear statement about where their honesty stops. Evaluating any specific claim they make about ingredients, clinical testing, or guarantees requires holding that statement in mind. The ingredients in pink Himalayan salt are real. The science of mineral deficiency is real. Elon Musk's endorsement is not, and everything downstream of that fabrication deserves proportionate skepticism.

This breakdown is part of Intel Services, our ongoing library of VSL and ad-copy analyses. If you're researching similar products in the joint health, pain relief, or mineral supplement space, keep reading, the pattern of hooks, authority signals, and persuasion structures documented here appears, in recognizable variations, across dozens of active campaigns.

Disclaimer: This article is for research and educational purposes only. It is not medical, legal, or financial advice, and it is not affiliated with the product or its makers. Always consult a qualified professional before making health or financial decisions.